| The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting PM Coplan, HD Chilcoat, SF Butler, EM Sellers, A Kadakia, ... Clinical Pharmacology & Therapeutics 100 (3), 275-286, 2016 | 88 | 2016 |
| The economic burden of schizophrenia in the United States A Kadakia, M Catillon, Q Fan, GR Williams, JR Marden, A Anderson, ... The Journal of clinical psychiatry 83 (6), 43278, 2022 | 63 | 2022 |
| Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis A Kadakia, C Dembek, V Heller, R Singh, J Uyei, K Hagi, T Nosaka, ... BMC psychiatry 21 (1), 249, 2021 | 41 | 2021 |
| Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia A Kadakia, Q Fan, J Shepherd, C Dembek, H Bailey, C Walker, ... Schizophrenia Research: Cognition 28, 100233, 2022 | 17 | 2022 |
| Systematic review and network meta-analysis: efficacy and safety of second-generation antipsychotics in youths with bipolar depression MP DelBello, A Kadakia, V Heller, R Singh, K Hagi, T Nosaka, A Loebel Journal of the American Academy of Child & Adolescent Psychiatry 61 (2), 243-254, 2022 | 16 | 2022 |
| CMF-regimen Preferred as First-course Chemotherapy for Older and Sicker Women With Breast Cancer: Findings From a SEER-Medicare–based Population Study A Kadakia, SS Rajan, S Abughosh, XL Du, ML Johnson American Journal of Clinical Oncology 38 (2), 165-173, 2015 | 15 | 2015 |
| The epidemiology of outpatient pain treatment in pediatrics S Baldridge, L Wallace, A Kadakia Journal of Pain Research, 913-921, 2018 | 14 | 2018 |
| Buprenorphine transdermal system utilization L Wallace, A Kadakia Postgraduate Medicine 129 (1), 81-86, 2017 | 12 | 2017 |
| A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum … A DeVeaugh-Geiss, A Kadakia, H Chilcoat, L Alexander, P Coplan The Journal of Pain 16 (6), 569-579. e1, 2015 | 8 | 2015 |
| The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population A Kadakia, BL Brady, C Dembek, GR Williams, JM Kent Journal of medical economics 25 (1), 87-98, 2022 | 7 | 2022 |
| Point-in-time survey of healthcare resource utilization, employment, quality of life and caregiver status by disease severity in patients with schizophrenia in the US A Kadakia, Q Fan, J Shepherd, H Bailey, C Dembek, C Walker, ... Current Medical Research and Opinion 38 (3), 469-478, 2022 | 6 | 2022 |
| (135) Comparison of the risk of opioid overdose among patients prescribed immediate-release and extended-release opioid analgesics P Coplan, A DeVeaugh-Geiss, A Kadakia The Journal of Pain 15 (4), S9, 2014 | 5 | 2014 |
| The economic burden of schizophrenia in the United States in 2019 A Kadakia, A Fan, J Marden, C Dembek, M Catillon, A Anderson, ... CNS spectrums 27 (2), 227-227, 2022 | 4 | 2022 |
| Burden of EPS in Commercial Patients With Schizophrenia Initiating Atypical Antipsychotics. A Kadakia, BL Brady, C Dembek, GR Williams, JM Kent American Journal of Managed Care 28 (9), 2022 | 3 | 2022 |
| Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study A Kadakia, C Dembek, Y Liu, C Dieyi, GR Williams Journal of Medical Economics 24 (1), 1212-1220, 2021 | 1 | 2021 |
| Changes in diagnosed addiction rates in patients prescribed OxyContin (ERO) or other opioids after introduction of ERO with abuse-deterrent properties PM Coplan, A Kadakia PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 27-27, 2015 | 1 | 2015 |
| Decrease in diagnosed abuse, addiction, and opioid poisoning among patients prescribed opioids after introduction of oxycontin with abuse-deterrent characteristics A Kadakia, P Coplan PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 472-473, 2015 | 1 | 2015 |
| Dose and duration of use among commercially insured adults prescribed immediate-release (IR) or extended-release (ER) oxycodone A DeVeaugh-Geiss, P Coplan, A Kadakia PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 130-130, 2015 | 1 | 2015 |
| Changes in diagnosed addiction rates in patients prescribed opioids after introduction of OxyContin with abuse-deterrent properties P Coplan, A Kadakia Drug and Alcohol Dependence 100 (156), e48, 2015 | 1 | 2015 |
| Duration of use of extended-release oxycodone and morphine among adults with cancer and non-cancer pain A DeVeaugh-Geiss, A Kadakia, H Chilcoat, P Coplan The Journal of Pain 14 (4), S75, 2013 | 1 | 2013 |
